Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pralatrexate vs Erlotinib in Advanced NSCLC
NCT00606502Phase 2Completed
- Sponsor
- Spectrum Pharmaceuticals, Inc.
- Start
- Jan 2008
- Primary completion
- Jun 2010
- Modality
- Small Molecules
- Countries
- 6
01
Overview
A Phase 2 trial of pralatrexate in non-small cell lung cancer (NSCLC), sponsored by Spectrum Pharmaceuticals, Inc.. Started Jan 2008; status: completed.
02
Drugs
pralatrexate
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT00606502.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00606502.